Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis

Immunity

Volumn 45, Issue 2, 2016, Pages 389-401

  Schietinger, Andrea ^a,b,c   Philip, Mary ^a,b   Krisnawan, Varintra E ^a,b   Chiu, Edison Y ^b   Delrow, Jeffrey J ^c   Basom, Ryan S ^c   Lauer, Peter ^d   Brockstedt, Dirk G ^d   Knoblaugh, Sue E ^c   Hämmerling, Günter J ^e   Schell, Todd D ^f   Garbi, Natalio ^e,g   Greenberg, Philip D ^b,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d Aduro BioTech Inc   (United States)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f PENN STATE COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; CYTOCHROME P450 2B4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DUAL SPECIFICITY PHOSPHATASE 6; FOXP1 PROTEIN; GAMMA INTERFERON; GRANZYME B; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HERMES ANTIGEN; INHIBITOR OF DIFFERENTIATION 2; INTERLEUKIN 10; KI 67 ANTIGEN; KRUPPEL LIKE FACTOR 2; L SELECTIN; LAG3 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 12; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE SHP 2; T LYMPHOCYTE RECEPTOR; TAMOXIFEN; TRANSCRIPTION FACTOR 7; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR T BET; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VIRUS LARGE T ANTIGEN; CANCER VACCINE; VIRUS T ANTIGEN;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CHROMATIN; CYTOKINE PRODUCTION; EFFECTOR CELL; HUMAN; INFECTION; LIVER CELL CARCINOMA; LYMPHOCYTE DIFFERENTIATION; MELANOMA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR MICROENVIRONMENT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; C57BL MOUSE; CELL AGING; CELL CULTURE; CELL DIFFERENTIATION; CHEMICALLY INDUCED; DISEASE MODEL; IMMUNOLOGY; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; PROCEDURES; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CANCER VACCINES; CARCINOGENESIS; CD8-POSITIVE T-LYMPHOCYTES; CELL AGING; CELL DIFFERENTIATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; TAMOXIFEN; TUMOR MICROENVIRONMENT;

EID: 84994330192     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2016.07.011     Document Type: Article

References (57)

1. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., Bignell, G.R., Bolli, N., Borg, A., Børresen-Dale, A.L., et al. Australian Pancreatic Cancer Genome Initiative ICGC Breast Cancer Consortium ICGC MMML-Seq Consortium, ICGC PedBrain. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
2. + T cells in metastases from melanoma patients. J. Clin. Invest. 121 (2011), 2350–2360.
3. Barber, D.L., Wherry, E.J., Masopust, D., Zhu, B., Allison, J.P., Sharpe, A.H., Freeman, G.J., Ahmed, R., Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 (2006), 682–687.
4. Blackburn, S.D., Shin, H., Haining, W.N., Zou, T., Workman, C.J., Polley, A., Betts, M.R., Freeman, G.J., Vignali, D.A., Wherry, E.J., Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10 (2009), 29–37.
5. Brahmer, J.R., Tykodi, S.S., Chow, L.Q., Hwu, W.J., Topalian, S.L., Hwu, P., Drake, C.G., Camacho, L.H., Kauh, J., Odunsi, K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366 (2012), 2455–2465.
6. Brockstedt, D.G., Giedlin, M.A., Leong, M.L., Bahjat, K.S., Gao, Y., Luckett, W., Liu, W., Cook, D.N., Portnoy, D.A., Dubensky, T.W. Jr., Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc. Natl. Acad. Sci. USA 101 (2004), 13832–13837.
7. Comerford, S.A., Schultz, N., Hinnant, E.A., Klapproth, S., Hammer, R.E., Comparative analysis of SV40 17kT and LT function in vivo demonstrates that LT's C-terminus re-programs hepatic gene expression and is necessary for tumorigenesis in the liver. Oncogenesis, 1, 2012, e28.
8. Crespo, J., Sun, H., Welling, T.H., Tian, Z., Zou, W., T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr. Opin. Immunol. 25 (2013), 214–221.
9. Cui, W., Kaech, S.M., Generation of effector CD8+ T cells and their conversion to memory T cells. Immunol. Rev. 236 (2010), 151–166.
10. Cullen, J.M., Sandgren, E.P., Brinster, R.L., Maronpot, R.R., Histologic characterization of hepatic carcinogenesis in transgenic mice expressing SV40 T-antigens. Vet. Pathol. 30 (1993), 111–118.
11. Endharti, A.T., Rifa'I, M., Shi, Z., Fukuoka, Y., Nakahara, Y., Kawamoto, Y., Takeda, K., Isobe, K., Suzuki, H., Cutting edge: CD8+CD122+ regulatory T cells produce IL-10 to suppress IFN-gamma production and proliferation of CD8+ T cells. J. Immunol. 175 (2005), 7093–7097.
12. Gabrilovich, D.I., Ostrand-Rosenberg, S., Bronte, V., Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12 (2012), 253–268.
13. Giordano, M., Henin, C., Maurizio, J., Imbratta, C., Bourdely, P., Buferne, M., Baitsch, L., Vanhille, L., Sieweke, M.H., Speiser, D.E., et al. Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. EMBO J. 34 (2015), 2042–2058.
14. + tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124 (2014), 2246–2259.
15. Gubin, M.M., Zhang, X., Schuster, H., Caron, E., Ward, J.P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C.D., Krebber, W.J., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515 (2014), 577–581.
16. Hamzah, J., Jugold, M., Kiessling, F., Rigby, P., Manzur, M., Marti, H.H., Rabie, T., Kaden, S., Gröne, H.J., Hämmerling, G.J., et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453 (2008), 410–414.
17. Hellström, I., Hellström, K.E., Pierce, G.E., Yang, J.P., Cellular and humoral immunity to different types of human neoplasms. Nature 220 (1968), 1352–1354.
18. Hogquist, K.A., Jameson, S.C., Heath, W.R., Howard, J.L., Bevan, M.J., Carbone, F.R., T cell receptor antagonist peptides induce positive selection. Cell 76 (1994), 17–27.
19. Joyce, J.A., Fearon, D.T., T cell exclusion, immune privilege, and the tumor microenvironment. Science 348 (2015), 74–80.
20. Kaech, S.M., Cui, W., Transcriptional control of effector and memory CD8+ T cell differentiation. Nat. Rev. Immunol. 12 (2012), 749–761.
21. Khalili, J.S., Hanson, R.W., Szallasi, Z., In silico prediction of tumor antigens derived from functional missense mutations of the cancer gene census. OncoImmunology 1 (2012), 1281–1289.
22. Kubuschok, B., Neumann, F., Breit, R., Sester, M., Schormann, C., Wagner, C., Sester, U., Hartmann, F., Wagner, M., Remberger, K., et al. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. Clin. Cancer Res. 12 (2006), 1365–1372.
23. Kurachi, M., Barnitz, R.A., Yosef, N., Odorizzi, P.M., DiIorio, M.A., Lemieux, M.E., Yates, K., Godec, J., Klatt, M.G., Regev, A., et al. The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells. Nat. Immunol. 15 (2014), 373–383.
24. Lennerz, V., Fatho, M., Gentilini, C., Frye, R.A., Lifke, A., Ferel, D., Wölfel, C., Huber, C., Wölfel, T., The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc. Natl. Acad. Sci. USA 102 (2005), 16013–16018.
25. Linnemann, C., van Buuren, M.M., Bies, L., Verdegaal, E.M., Schotte, R., Calis, J.J., Behjati, S., Velds, A., Hilkmann, H., Atmioui, D.E., et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat. Med. 21 (2015), 81–85.
26. Lu, Y.C., Yao, X., Li, Y.F., El-Gamil, M., Dudley, M.E., Yang, J.C., Almeida, J.R., Douek, D.C., Samuels, Y., Rosenberg, S.A., Robbins, P.F., Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J. Immunol. 190 (2013), 6034–6042.
27. Mittrücker, H.W., Kursar, M., Köhler, A., Hurwitz, R., Kaufmann, S.H., Role of CD28 for the generation and expansion of antigen-specific CD8(+) T lymphocytes during infection with Listeria monocytogenes. J. Immunol. 167 (2001), 5620–5627.
28. Noy, R., Pollard, J.W., Tumor-associated macrophages: from mechanisms to therapy. Immunity 41 (2014), 49–61.
29. Ostrand-Rosenberg, S., Horn, L.A., Haile, S.T., The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J. Immunol. 193 (2014), 3835–3841.
30. Paley, M.A., Kroy, D.C., Odorizzi, P.M., Johnnidis, J.B., Dolfi, D.V., Barnett, B.E., Bikoff, E.K., Robertson, E.J., Lauer, G.M., Reiner, S.L., Wherry, E.J., Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 338 (2012), 1220–1225.
31. Perez-Gracia, J.L., Labiano, S., Rodriguez-Ruiz, M.E., Sanmamed, M.F., Melero, I., Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Curr. Opin. Immunol. 27 (2014), 89–97.
32. Philip, M., Schietinger, A., Schreiber, H., Ribosomal versus non-ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4+ T cells. Immunology 130 (2010), 494–503.
33. Popovic, J., Li, L.P., Kloetzel, P.M., Leisegang, M., Uckert, W., Blankenstein, T., The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed. Blood 118 (2011), 946–954.
34. Quigley, M., Pereyra, F., Nilsson, B., Porichis, F., Fonseca, C., Eichbaum, Q., Julg, B., Jesneck, J.L., Brosnahan, K., Imam, S., et al. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat. Med. 16 (2010), 1147–1151.
35. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
36. Robbins, P.F., El-Gamil, M., Li, Y.F., Kawakami, Y., Loftus, D., Appella, E., Rosenberg, S.A., A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183 (1996), 1185–1192.
37. Robbins, P.F., Lu, Y.C., El-Gamil, M., Li, Y.F., Gross, C., Gartner, J., Lin, J.C., Teer, J.K., Cliften, P., Tycksen, E., et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19 (2013), 747–752.
38. Savage, P.A., Malchow, S., Leventhal, D.S., Basic principles of tumor-associated regulatory T cell biology. Trends Immunol. 34 (2013), 33–40.
39. Schietinger, A., Greenberg, P.D., Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 35 (2014), 51–60.
40. Schietinger, A., Philip, M., Schreiber, H., Specificity in cancer immunotherapy. Semin. Immunol. 20 (2008), 276–285.
41. Schietinger, A., Delrow, J.J., Basom, R.S., Blattman, J.N., Greenberg, P.D., Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science 335 (2012), 723–727.
42. Shin, H., Blackburn, S.D., Intlekofer, A.M., Kao, C., Angelosanto, J.M., Reiner, S.L., Wherry, E.J., A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. Immunity 31 (2009), 309–320.
43. Sinnathamby, G., Lauer, P., Zerfass, J., Hanson, B., Karabudak, A., Krakover, J., Secord, A.A., Clay, T.M., Morse, M.A., Dubensky, T.W. Jr., et al. Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines. J. Immunother. 32 (2009), 856–869.
44. Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J.M., Desrichard, A., Walsh, L.A., Postow, M.A., Wong, P., Ho, T.S., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371 (2014), 2189–2199.
45. Stahl, S., Sacher, T., Bechtold, A., Protzer, U., Ganss, R., Hämmerling, G.J., Arnold, B., Garbi, N., Tumor agonist peptides break tolerance and elicit effective CTL responses in an inducible mouse model of hepatocellular carcinoma. Immunol. Lett. 123 (2009), 31–37.
46. Staveley-O'Carroll, K., Schell, T.D., Jimenez, M., Mylin, L.M., Tevethia, M.J., Schoenberger, S.P., Tevethia, S.S., In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. J. Immunol. 171 (2003), 697–707.
47. Thomas, R.M., Gao, L., Wells, A.D., Signals from CD28 induce stable epigenetic modification of the IL-2 promoter. J. Immunol. 174 (2005), 4639–4646.
48. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454.
49. Tran, E., Turcotte, S., Gros, A., Robbins, P.F., Lu, Y.C., Dudley, M.E., Wunderlich, J.R., Somerville, R.P., Hogan, K., Hinrichs, C.S., et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344 (2014), 641–645.
50. van Rooij, N., van Buuren, M.M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L.J., Behjati, S., Hilkmann, H., El Atmioui, D., et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31 (2013), e439–e442.
51. Viré, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.M., et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439 (2006), 871–874.
52. Wherry, E.J., Ha, S.J., Kaech, S.M., Haining, W.N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J.N., Barber, D.L., Ahmed, R., Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27 (2007), 670–684.
53. Willimsky, G., Blankenstein, T., Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437 (2005), 141–146.
54. Wolchok, J.D., Chan, T.A., Cancer: Antitumour immunity gets a boost. Nature 515 (2014), 496–498.
55. Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.H., Beach, D., A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269 (1995), 1281–1284.
56. Youngblood, B., Oestreich, K.J., Ha, S.J., Duraiswamy, J., Akondy, R.S., West, E.E., Wei, Z., Lu, P., Austin, J.W., Riley, J.L., et al. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity 35 (2011), 400–412.
57. Zippelius, A., Batard, P., Rubio-Godoy, V., Bioley, G., Liénard, D., Lejeune, F., Rimoldi, D., Guillaume, P., Meidenbauer, N., Mackensen, A., et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 64 (2004), 2865–2873.